Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for…

Abstract

A lthough the API-CAT (APIxaban Cancer Asso- ciated Thrombosis) trial demonstrated the noninferiority and safety of reduced-dose apixaban (2.5 mg twice daily) compared with standard full-dose (5 mg twice daily) for patients who completed at least 6 months of anticoagulant therapy to evaluate extended treatment for cancer-associated thrombosis (CAT), recurrent venous thromboembolism (VTE) still occurred in 2.5% of patients (42 of 1,766). 1 Recurrent VTE during the extended anticoagulant treatment period represents treatment failure and remains a clinical concern in CAT associated with substantial morbidity, impaired quality of life, hospitalizations, and increased mortality.[2][3][4] Although several factors associated with recurrent VTE have been identified during the first 6 months after the index event, the determinants of recurrence beyond this period remain poorly characterized.In this ancillary analysis of the API-CAT randomized double-blind trial (NCT03692065), we evaluated 1,766 adults with active cancer who completed at least 6 months of anticoagulation and received extended apixaban for an additional 12 months.1,4 Eligible patients had no objectively documented symptomatic recurrent VTE at study entry.Primary outcome was centrally adjudicated recurrent VTE during the 12-month follow-up, defined as a composite of recurrent symptomatic VTE, incidental proximal deep vein thrombosis or pulmonary embolism, or VTE-related death.The Comité de Protection des Personnes Ile de France II provided ethics approval (2018-05-01 RIPH 1).To prevent model over-

The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis
Lisbeth Eischer, Paul A Kyrle, Alexandra Kaider +18
Research and Practice in Thrombosis and Haemostasis1 Sep 2026Peer-reviewedCC BY 4.0Full text1 citedGeneral biologyHAL
Potential role of neutrophil extracellular traps in ovarian cancer-associated venous thrombosis
Gaku Yamamoto, Mahiru Kawano, Mina Sakata +8
Scientific Reports20 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textImmunologyCrossref
Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study
Steve Raoul Noumegni, Romain Didier, Vincent Mansourati +11
Thrombosis Research17 Sep 2026Peer-reviewedCC BY-NC-ND 4.0Full text6 citedGeneral biologyHAL
Sex-specific Risks in Lung Cancer-Associated Thrombosis: Focus on Female Patients
Margaux Geier, Jessica Nguyen, Benjamin Auberger +8
Clinical and Applied Thrombosis/Hemostasis1 Sep 2026Peer-reviewedCC BY-NC 4.0Full textGeneral biologyHAL
A bicentric pilot study of apixaban and rivaroxaban quantification using a novel Point-Of-Care system in the emergency department
Cindy Tissier, Tiffany Madranges, Nicolas Peschanski +4
Research and Practice in Thrombosis and Haemostasis6 Nov 2026Peer-reviewedCC BY-NC-NDGeneral biologyHAL

Cite

BibTeX RIS

BibTeX

@article{mahe2026factors,
  title = {{Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis}},
  author = {Isabelle Mahé and Jean Chidiac and Marc Righini and Grégoire Le Gal and Frederikus Klok and Giancarlo Agnelli and Sebastian Szmit and Francis Cajfinger and Marie-Antoinette Sevestre and Philippe Grenier and Jérôme Alexandre and Francis Couturaud and Patrick Mismetti and Silvy Laporte and Céline Chapelle},
  journal = {JACC: CardioOncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.jaccao.2026.09.011},
  url = {https://u-picardie.hal.science/hal-05836692v1},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis
AU  - Isabelle Mahé
AU  - Jean Chidiac
AU  - Marc Righini
AU  - Grégoire Le Gal
AU  - Frederikus Klok
AU  - Giancarlo Agnelli
AU  - Sebastian Szmit
AU  - Francis Cajfinger
AU  - Marie-Antoinette Sevestre
AU  - Philippe Grenier
AU  - Jérôme Alexandre
AU  - Francis Couturaud
AU  - Patrick Mismetti
AU  - Silvy Laporte
AU  - Céline Chapelle
PY  - 2026
DA  - 2026/10/23
JO  - JACC: CardioOncology
DO  - 10.1016/j.jaccao.2026.09.011
UR  - https://u-picardie.hal.science/hal-05836692v1
AB  - A lthough the API-CAT (APIxaban Cancer Asso- ciated Thrombosis) trial demonstrated the noninferiority and safety of reduced-dose apixaban (2.5 mg twice daily) compared with standard full-dose (5 mg twice daily) for patients who completed at least 6 months of anticoagulant therapy to evaluate extended treatment for cancer-associated thrombosis (CAT), recurrent venous thromboembolism (VTE) still occurred in 2.5% of patients (42 of 1,766). 1 Recurrent VTE during the extended anticoagulant treatment period represents treatment failure and remains a clinical concern in CAT associated with substantial morbidity, impaired quality of life, hospitalizations, and increased mortality.[2][3][4] Although several factors associated with recurrent VTE have been identified during the first 6 months after the index event, the determinants of recurrence beyond this period remain poorly characterized.In this ancillary analysis of the API-CAT randomized double-blind trial (NCT03692065), we evaluated 1,766 adults with active cancer who completed at least 6 months of anticoagulation and received extended apixaban for an additional 12 months.1,4 Eligible patients had no objectively documented symptomatic recurrent VTE at study entry.Primary outcome was centrally adjudicated recurrent VTE during the 12-month follow-up, defined as a composite of recurrent symptomatic VTE, incidental proximal deep vein thrombosis or pulmonary embolism, or VTE-related death.The Comité de Protection des Personnes Ile de France II provided ethics approval (2018-05-01 RIPH 1).To prevent model over-
SN  - 2666-0873
ER  -

Abstract

Related

Cite